Kodiak Sciences Inc (KOD) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kodiak Sciences Inc (KOD) has a cash flow conversion efficiency ratio of -0.757x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-46.24 Million) by net assets ($61.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Kodiak Sciences Inc (KOD) market capitalisation for the company's overall valuation and market capitalisation.
Kodiak Sciences Inc - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Kodiak Sciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Kodiak Sciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kodiak Sciences Inc ranked by their cash flow conversion efficiency. See KOD debt coverage from operations to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suzhou Crystal Clear Chemical Co Ltd
SHE:300655
|
0.062x |
|
Jiangzhong Pharmaceutical Co Ltd
SHG:600750
|
-0.001x |
|
Greencore Group plc
F:GCG
|
-0.007x |
|
Smartfit Escola de Ginástica e Dança S.A
SA:SMFT3
|
0.059x |
|
Grand Plastic Technology
TWO:3131
|
0.189x |
|
Blackbaud Inc
NASDAQ:BLKB
|
0.682x |
|
Ningbo Huaxiang Electronic Co Ltd
SHE:002048
|
0.037x |
|
Shenzhen Overseas Chinese Town Co Ltd
SHE:000069
|
0.046x |
Annual Cash Flow Conversion Efficiency for Kodiak Sciences Inc (2016–2025)
The table below shows the annual cash flow conversion efficiency of Kodiak Sciences Inc from 2016 to 2025. View KOD share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $157.38 Million | $-136.01 Million | -0.864x | -10.70% |
| 2024-12-31 | $150.29 Million | $-117.32 Million | -0.781x | -34.56% |
| 2023-12-31 | $265.78 Million | $-154.18 Million | -0.580x | -22.56% |
| 2022-12-31 | $436.17 Million | $-206.46 Million | -0.473x | -72.26% |
| 2021-12-31 | $663.32 Million | $-182.27 Million | -0.275x | -183.50% |
| 2020-12-31 | $860.75 Million | $-83.43 Million | -0.097x | +14.49% |
| 2019-12-31 | $345.36 Million | $-39.15 Million | -0.113x | +66.10% |
| 2018-12-31 | $86.83 Million | $-29.03 Million | -0.334x | -230.17% |
| 2017-12-31 | $-68.74 Million | $-17.66 Million | 0.257x | -34.24% |
| 2016-12-31 | $-41.08 Million | $-16.05 Million | 0.391x | -- |
About Kodiak Sciences Inc
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in… Read more